Skip to main content
PMC home page
The British Journal of Ophthalmology logoLink to The British Journal of Ophthalmology
. 1993 Jun;77(6):344–348. doi: 10.1136/bjo.77.6.344

Effect of topical ketanserin administration on intraocular pressure.

C Costagliola 1, G Iuliano 1, M Rinaldi 1, V Russo 1, G Scibelli 1, L Mastropasqua 1
PMCID: PMC504527  PMID: 8318480

Abstract

The effect of topical ketanserin on intraocular pressure (IOP) in normotensive and hypertensive eyes was evaluated. The study was performed on 10 healthy volunteers and 10 glaucomatous patients. Systolic arterial blood pressure (SBP), diastolic arterial blood pressure (DBP), heart rate (HR), IOP, tonographic outflow facility, pupil diameter, corneal thickness, and tear secretion were recorded at baseline and at 1 hour intervals for 12 hours after topical administration of 0.5% ketanserin or placebo, given in a randomised, double masked, crossover fashion. The alternative treatment was given 1 week later. In all subjects ketanserin significantly lowered IOP, while no variations in SBP, DBP, HR, pupil diameter, corneal thickness, and tear secretion were found. When subjects received placebo no significant variations of IOP occurred. Total outflow facility, measured by conventional tonography, increased significantly after drug administration in all subjects. Ketanserin is effective up to 6 hours in control subjects and 9 hours in glaucomatous patients. The placebo did not induce any change in this component of the aqueous humour dynamic in normal or in glaucomatous eyes. The findings indicate that topical ketanserin might be added to the list of antiglaucomatous agents.

Full text

PDF
344

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Aberg G., Adler G., Wikberg J. Inhibition and facilitation of lacrimal flow by beta-adrenergic drugs. Acta Ophthalmol (Copenh) 1979 Apr;57(2):225–235. doi: 10.1111/j.1755-3768.1979.tb00486.x. [DOI] [PubMed] [Google Scholar]
  2. Cazzola M., D'Amato G., Lobefalo G., Guillaro B., Sepe J., Assogna G., Pietroletti R., Lauria D. Ketanserin, a new blocking agent of serotonin S2-receptors. Respiratory functional effects in chronic obstruction of the airways. Chest. 1987 Nov;92(5):863–866. doi: 10.1378/chest.92.5.863. [DOI] [PubMed] [Google Scholar]
  3. Chang F. W., Burke J. A., Potter D. E. Mechanism of the ocular hypotensive action of ketanserin. J Ocul Pharmacol. 1985 Summer;1(2):137–147. doi: 10.1089/jop.1985.1.137. [DOI] [PubMed] [Google Scholar]
  4. Collignon P. Cardiovascular and pulmonary effects of beta-blocking agents: implications for their use in ophthalmology. Surv Ophthalmol. 1989 Apr;33 (Suppl):455–460. doi: 10.1016/0039-6257(89)90087-8. [DOI] [PubMed] [Google Scholar]
  5. Costagliola C., Scibelli G., Fasano M. L., Ferrara L. A., Mastropasqua L. Effect of oral ketanserin administration on intraocular pressure in glaucomatous patients. Exp Eye Res. 1991 May;52(5):507–510. doi: 10.1016/0014-4835(91)90050-o. [DOI] [PubMed] [Google Scholar]
  6. Demoulin J. C., Bertholet M., Soumagne D., David J. L., Kulbertus H. E. 5-HT2-receptor blockade in the treatment of heart failure. A preliminary study. Lancet. 1981 May 30;1(8231):1186–1188. doi: 10.1016/s0140-6736(81)92352-7. [DOI] [PubMed] [Google Scholar]
  7. Hedner T., Persson B., Berglund G. Ketanserin, a novel 5-hydroxytryptamine antagonist: monotherapy in essential hypertension. Br J Clin Pharmacol. 1983 Aug;16(2):121–125. doi: 10.1111/j.1365-2125.1983.tb04974.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Kalkman H. O., Timmermans P. B., Van Zwieten P. A. Characterization of the antihypertensive properties of ketanserin (R 41 468) in rats. J Pharmacol Exp Ther. 1982 Jul;222(1):227–231. [PubMed] [Google Scholar]
  9. Karnezis T. A., Murphy M. B., Weber R. R., Nelson K. S., Tripathi B. J., Tripathi R. C. Effects of selective dopamine-1 receptor activation on intraocular pressure in man. Exp Eye Res. 1988 Nov;47(5):689–697. doi: 10.1016/0014-4835(88)90036-x. [DOI] [PubMed] [Google Scholar]
  10. Krootila K., Palkama A., Uusitalo H. Effect of serotonin and its antagonist (ketanserin) on intraocular pressure in the rabbit. J Ocul Pharmacol. 1987 Winter;3(4):279–290. doi: 10.1089/jop.1987.3.279. [DOI] [PubMed] [Google Scholar]
  11. Kurowski M. Bioavailability and pharmacokinetics of ketanserin in elderly subjects. Eur J Clin Pharmacol. 1985;28(4):411–417. doi: 10.1007/BF00544359. [DOI] [PubMed] [Google Scholar]
  12. Leier C. V., Baker N. D., Weber P. A. Cardiovascular effects of ophthalmic timolol. Ann Intern Med. 1986 Feb;104(2):197–199. doi: 10.7326/0003-4819-104-2-197. [DOI] [PubMed] [Google Scholar]
  13. Lemp M. A., Hamill J. R., Jr Factors affecting tear film breakup in normal eyes. Arch Ophthalmol. 1973 Feb;89(2):103–105. doi: 10.1001/archopht.1973.01000040105007. [DOI] [PubMed] [Google Scholar]
  14. Marwood J. F., Stokes G. S. Serotonin (5HT) and its antagonists: involvement in the cardiovascular system. Clin Exp Pharmacol Physiol. 1984 Sep-Oct;11(5):439–455. doi: 10.1111/j.1440-1681.1984.tb00852.x. [DOI] [PubMed] [Google Scholar]
  15. McMahon C. D., Shaffer R. N., Hoskins H. D., Jr, Hetherington J., Jr Adverse effects experienced by patients taking timolol. Am J Ophthalmol. 1979 Oct;88(4):736–738. doi: 10.1016/0002-9394(79)90674-3. [DOI] [PubMed] [Google Scholar]
  16. Norn M. S. Desiccation of the precorneal film. I. Corneal wetting-time. Acta Ophthalmol (Copenh) 1969;47(4):865–880. doi: 10.1111/j.1755-3768.1969.tb03711.x. [DOI] [PubMed] [Google Scholar]
  17. Osborne N. N. The occurrence of serotonergic nerves in the bovine cornea. Neurosci Lett. 1983 Jan 31;35(1):15–18. doi: 10.1016/0304-3940(83)90519-0. [DOI] [PubMed] [Google Scholar]
  18. Osborne N. N., Tobin A. B. Serotonin-accumulating cells in the iris-ciliary body and cornea of various species. Exp Eye Res. 1987 Jun;44(6):731–745. doi: 10.1016/s0014-4835(87)80037-4. [DOI] [PubMed] [Google Scholar]
  19. Schoene R. B., Abuan T., Ward R. L., Beasley C. H. Effects of topical betaxolol, timolol, and placebo on pulmonary function in asthmatic bronchitis. Am J Ophthalmol. 1984 Jan;97(1):86–92. doi: 10.1016/0002-9394(84)90450-1. [DOI] [PubMed] [Google Scholar]
  20. Tobin A. B., Unger W., Osborne N. N. Evidence for the presence of serotonergic nerves and receptors in the iris-ciliary body complex of the rabbit. J Neurosci. 1988 Oct;8(10):3713–3721. doi: 10.1523/JNEUROSCI.08-10-03713.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Weinreb R. N., van Buskirk E. M., Cherniack R., Drake M. M. Long-term betaxolol therapy in glaucoma patients with pulmonary disease. Am J Ophthalmol. 1988 Aug 15;106(2):162–167. doi: 10.1016/0002-9394(88)90828-8. [DOI] [PubMed] [Google Scholar]
  22. Yablonski M. E., Novack G. D., Burke P. J., Cook D. J., Harmon G. The effect of levobunolol on aqueous humor dynamics. Exp Eye Res. 1987 Jan;44(1):49–54. doi: 10.1016/s0014-4835(87)80024-6. [DOI] [PubMed] [Google Scholar]
  23. Yablonski M. E., Zimmerman T. J., Waltman S. R., Becker B. A fluorophotometric study of the effect of topical timolol on aqueous humor dynamics. Exp Eye Res. 1978 Aug;27(2):135–142. doi: 10.1016/0014-4835(78)90083-0. [DOI] [PubMed] [Google Scholar]
  24. van Setten G. B., Stephens R., Tervo T., Salonen E. M., Tarkkanen A., Vaheri A. Effects of the Schirmer test on the fibrinolytic system in the tear fluid. Exp Eye Res. 1990 Feb;50(2):135–141. doi: 10.1016/0014-4835(90)90223-h. [DOI] [PubMed] [Google Scholar]

Articles from The British Journal of Ophthalmology are provided here courtesy of BMJ Publishing Group

RESOURCES